4//SEC Filing
Basil Michelle L 4
Accession 0001127602-24-016164
CIK 0000313143other
Filed
May 20, 8:00 PM ET
Accepted
May 21, 5:46 PM ET
Size
12.1 KB
Accession
0001127602-24-016164
Insider Transaction Report
Form 4
Basil Michelle L
EVP and General Counsel
Transactions
- Award
Common Stock
2024-05-17+4,178→ 32,861 total - Tax Payment
Common Stock
2024-05-17$95.73/sh−669$64,043→ 28,683 total - Award
Non-qualified Stock Option (Right to Buy)
2024-05-17+9,183→ 9,183 totalExercise: $95.73Exp: 2031-05-17→ Common Stock (9,183 underlying) - Sale
Common Stock
2024-05-17$95.00/sh−1,073$101,935→ 29,352 total - Sale
Common Stock
2024-05-20$95.08/sh−1,604$152,508→ 31,257 total
Footnotes (6)
- [F1]Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023).
- [F2]This number includes unvested restricted stock units ("RSUs") previously reported.
- [F3]Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.
- [F4]The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
- [F5]Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
- [F6]Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.
Documents
Issuer
HAEMONETICS CORP
CIK 0000313143
Entity typeother
Related Parties
1- filerCIK 0001699629
Filing Metadata
- Form type
- 4
- Filed
- May 20, 8:00 PM ET
- Accepted
- May 21, 5:46 PM ET
- Size
- 12.1 KB